Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...

NORTHAMPTON, MA / ACCESS Newswire / June 24, 2025 / Kim Canady was only nine years old in 1996 when she faced the ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...